Taysha discontinues TSHA-120 in GAN; extends cash runway to Q4 2025 for TSHA-102

Taysha Gene Therapies, Inc.

Taysha discontinues TSHA-120 for giant axonal neuropathy after FDA Type C feedback cited study design challenges for BLA.
Astellas Gene Therapies declined its option to license TSHA-120.
Cash runway extended into Q4 2025 by prioritizing TSHA-102 for Rett syndrome.
Ongoing REVEAL Phase 1/2 trial for TSHA-102 in adults; pediatric trial planned.
Taysha to pursue external strategic options for TSHA-120 to enable further development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.